Ascendia

  MARKET NEWS

Nemera and SCHOTT Pharma deliver verified pen injector platform with sterile cartridge system
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
Samsung Biologics announces all-cash offer to acquire PolyPeptide
Eli Lilly Makes $2.8 Billion Neuropsychiatry Acquisition

  EXPERT CONTENT & RESOURCES

Nina Bauer

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

eBook: Understanding the Foundation of LNP Formulation Success

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

  COMPANY PROFILE

Company Logo

Ascendia Pharmaceutical Solutions is drug development teams’ fast, flexible, and first time right CDMO partner. It makes the Impossible Possible through a comprehensive suite of pre-formulation, formulation development, cGMP manufacturing, and ICH stability services for a variety of dosage forms and clinical trial materials (CTM), using proprietary enabling nanotechnologies. The company built its success on its customer-centric BEST philosophy (Brilliant technology, Excellent service, Superior quality, and Trust).

Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 5 – Injection Devices
August 12 – Lyophilization Manufacturing
August 19 – Excipients
August 26 – Gene Therapy